Application of Autologous Tumor Vaccine as an Adjuvant Immunotherapy in the Treatment of Metastatic Renal Cell Carcinoma.
- Author:
Dong Soo PARK
1
;
Do Yon OH
;
Myung Seo KANG
;
Hee Jung AN
;
Sun Ju LEE
;
Nam Keun KIM
Author Information
1. Department of Urology, College of Medicine, Pochon CHA University, Seongnam, Korea. dsparkmd@cha.ac.kr
- Publication Type:Case Report
- Keywords:
Renal cell carcinoma;
Vaccines
- MeSH:
Carcinoma, Renal Cell*;
Chemoradiotherapy;
Humans;
Immunization;
Immunotherapy*;
Interferon-alpha;
Interleukin-2;
Neoplasm Metastasis;
Recurrence;
Vaccines
- From:Korean Journal of Urology
2005;46(10):1106-1109
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
About 50% of renal cell carcinoma patients initially present with a regional or distant metastatic disease. Attempts to treat metastatic renal cell carcinomas have been directed at cytokine-based immunotherapy. Response rates of interleukin-2-based immunotherapy of 5 to 29% have been reported in this disease. Immunization as a mechanism to recruit host antitumor responses is increasingly being described as a potentially effective and less toxic approach for the treatment of metastatic and high-risk primary cancers. An autologous renal cell cancer vaccine has been applied at our institution for the prevention of recurrence or metastasis in locally advanced cases for more than one year. Herein, two metastatic renal cell carcinoma cases, which failed to show a response to initial immunotherapy or chemoradiotherapy, which were successfully treated with IL-2 (Aldesleukin) and interferon-alpha as autologous cancer vaccine adjuvants is reported.
